Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 17855660
Zhang Y, Wang Z, Magnuson NS (2007) Pim-1 kinase-dependent phosphorylation of p21Cip1/WAF1 regulates its stability and cellular localization in H1299 cells. Mol Cancer Res 5, 909-22 17855660
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T145-p - p21Cip1 (human)
Modsite: QGRkRRQtsMTDFyH SwissProt Entrez-Gene
Orthologous residues
p21Cip1 (human): T145‑p, p21Cip1 (mouse): T140‑p, p21Cip1 (dog): T113‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  3T3 (fibroblast), COS (fibroblast), NCI-H1299 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  green monkey, human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Pim1 (human)
Comments:  T145 is primary site but if mutated then S146 is phosphorylated
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Pim1 (human) transfection of inactive enzyme, pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, transfection of wild-type enzyme, phospho-antibody
KINASE Akt1 (human) transfection of constitutively active enzyme, pharmacological inhibitor of upstream enzyme, phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Pim1 (human) increase
LY294002 decrease
wortmannin no change compared to control
Downstream Regulation
Effect of modification (function):  molecular association, regulation, protein stabilization
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
PCNA (human) Disrupts co-immunoprecipitation

S146-p - p21Cip1 (human)
Modsite: GRkRRQtsMTDFyHs SwissProt Entrez-Gene
Orthologous residues
p21Cip1 (human): S146‑p, p21Cip1 (mouse): S141‑p, p21Cip1 (dog): S114‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  3T3 (fibroblast), COS (fibroblast), NCI-H1299 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  green monkey, human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Pim1 (human)
Comments:  T145 is primary site but if mutated then S146 is phosphorylated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Pim1 (human) increase
LY294002 increase
wortmannin no change compared to control
Downstream Regulation
Effect of modification (function):  intracellular localization
Effect of modification (process):  cell growth, altered